Your search found 2 Results
[Geneva, Switzerland], WHO, 2016 May 27.  p. (EB139/8)WHO has issued a report that is strongly supportive of mHealth. New priorities for WHO in the area of mHealth include: to support and strengthen ongoing efforts to build evidence-based guidance on the use of mHealth in order to advance integrated person-centred health services and universal health coverage; to provide guidance on mHealth adoption, management and evaluation in order to aid good governance and investment decisions. These could include guidance to inform the development of national programmes and strategies, and the development of standard operating procedures; to work with Member States and partners to build platforms for sharing evidence, experience and good practices in mHealth implementation as a way to achieving the Sustainable Development Goals. These could include building on existing networks to create regional hubs of knowledge and excellence on mHealth; to support building capacity and the empowerment of health workers and their beneficiary populations to use information and communication technologies, in order to foster their engagement and accountability, and to catalyse and monitor progress on specific Sustainable Development Goals using mHealth.
BULLETIN OF THE WORLD HEALTH ORGANIZATION. 1985; 63(2):241-8.The WHO memorandum outlines the present situation regarding pertussis vaccines, discusses ways to evaluate candidate vaccines, and identifies future research needs. Most existing whooping cough vaccines are whole-cell vaccines, combined with diphtheria and tetanus toxoid adsorbed on an aluminum or calcium carrier. As whole bacterial cells, they contain a complex array of at least 7 toxins and antigens, and display a narrow margin between potency and toxicity. The Japanese introduced an acellular vaccine, admittedly sometimes less potent, called the Precipitated Purified Pertussis Vaccine, in 1981. This material contains far less bacterial mass, notably less endotoxin, and consequently produces less fever, erythema and induration. WHO has not yet established minimum requirements for standardization; even the mouse potency assay may not be suitable. There are techniques, however, which will measure amounts of component antigens and toxicity. Conflicting results on assays of potency and immunogenicity will have to be resolved. Besides the obvious need for large clinical trials of defined vaccines, a whole range of research needs were suggested, from genetic studies of the organism to specific details of the host response. It is generally agreed that a less reactogenic and more effective pertussis vaccine is needed and feasible.